Skip to main content

Repligen Corporation

corporate_fare Company Profile

Repligen Corporation

RGEN·NASDAQ·Life Sciences·CIK 0000730272

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems designed to increase efficiencies and flexibility in manufacturing biological drugs. The company's primary customers are global biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies (integrators) that face pressures related to production cost, capacity, quality, and time. Repligen's products are used in the production of critical biologic drugs, including monoclonal antibodies (mAbs) and mAb derivatives like antibody drug conjugates, recombinant proteins, RNA-based therapeutics and vaccines, and cell and gene therapies (C&GT). The company operates as one bioprocessing business, offering a comprehensive suite of products for both upstream and downstream processes in biological drug manufacturing. With over 40 years of industry expertise, Repligen has developed a broad and diversified product portfolio. The company pursues growth through internal innovation, commercial leverage, and targeted acquisitions. Repligen's corporate headquarters are in Waltham, Massachusetts, with additional administrative and manufacturing operations located worldwide.

Repligen Corporation (NASDAQ:RGEN) is a publicly traded company in the Life Sciences sector. Wiseek monitors RGEN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Repligen to Acquire BioLife Solutions in $1.5B Deal, Expanding Cell Therapy Capabilities
  • Repligen to Acquire BioLife Solutions, Adding Market-Leading Biopreservation Media
  • Shareholders Re-elect Directors, Approve Exec Pay Amidst Notable Dissent
  • Repligen Reports Strong Q1 Earnings Amidst Divestiture Loss and Ongoing Internal Control Weaknesses
  • Repligen Reports Strong Q1 Results, Exceeds Expectations, and Raises Full-Year Adjusted EPS Guidance

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$738.26M
Net Income
$48.89M
Diluted EPS
$0.86
Op. Cash Flow
$117.42M
Free Cash Flow
$93.9M
Gross Profit
$386.25M
Operating Income
$55.17M
Cash & Equivalents
$566.02M
Total Debt
$542.21M
Debt / Equity
0.26×
Net Margin
6.6%
Shares Outstanding
56.33M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-076528
Browse all tickers starting with R →
$131.96
52-week range · as of 2026-07-22 $100.99 – $175.77
Market cap
$7.45B
Volume
1.4M (1.2× avg)
3-mo avg 1.2M
Live data · 2026-07-27 06:55 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed RGEN - Latest Insights

RGEN
Jul 22, 2026, 8:56 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $131.01
Real-time Price: $131.96 info
Change: +$0.950 (+0.73%) info
Market Cap: $7.447B info
RGEN
Jul 22, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $136.97
Real-time Price: $131.96 info
Change: -$5.01 (-4%) info
Market Cap: $7.447B info
RGEN
May 15, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $103.38
Real-time Price: $131.96 info
Change: +$28.58 (+28%) info
Market Cap: $7.447B info
RGEN
May 06, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $125.76
Real-time Price: $131.96 info
Change: +$6.20 (+5%) info
Market Cap: $7.447B info
RGEN
May 05, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $116.80
Real-time Price: $131.96 info
Change: +$15.16 (+13%) info
Market Cap: $7.447B info
RGEN
May 05, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $116.80
Real-time Price: $131.96 info
Change: +$15.16 (+13%) info
Market Cap: $7.447B info
RGEN
Apr 27, 2026, 4:03 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $118.90
Real-time Price: $131.96 info
Change: +$13.06 (+11%) info
Market Cap: $7.447B info
RGEN
Apr 02, 2026, 4:13 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $117.78
Real-time Price: $131.96 info
Change: +$14.18 (+12%) info
Market Cap: $7.447B info
RGEN
Feb 26, 2026, 4:03 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $133.65
Real-time Price: $131.96 info
Change: -$1.69 (-1%) info
Market Cap: $7.447B info
RGEN
Feb 24, 2026, 7:33 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $137.29
Real-time Price: $131.96 info
Change: -$5.33 (-4%) info
Market Cap: $7.447B info